Clinical Trial Update: Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the safety and potential efficacy of SANGUINATE infusion in patients at risk of delayed cerebral ischemia after subarachnoid hem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Ischemia
• Subarachnoid Hemorrhage

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Cerebral Ischemia | Phase 2 | Status: COMPLETED